Department of Justice
U.S. Attorney’s Office
Middle District of Florida
FOR IMMEDIATE RELEASE
Thursday, January 27, 2022
Jacksonville, Florida – U.S. District Judge Timothy J. Corrigan has sentenced Jerome Clampitt II to six months in federal prison, followed by six months of home detention for tampering with a consumer product, specifically, injectable fentanyl.
Clampitt had pleaded guilty on October 27, 2021.
According to court documents, on January 30, 2020, Clampitt, a registered nurse, was working a night shift in the intensive care unit of a hospital in Jacksonville. A patient under Clampitt’s care was prescribed and receiving an intravenous dose of fentanyl, which is used both as a pain medication and as anesthesia. Two fellow employees saw Clampitt using a syringe to inject a substance into the device that dispensed fentanyl into the patient, when there was no medically valid reason for Clampitt to do so. Laboratory testing eventually determined that the patient’s dose of fentanyl had been diluted with saline.
When interviewed by law enforcement officers, Clampitt eventually admitted that he had diverted drugs from patients at the hospital for personal use. During that interview, however, he denied diluting patient drugs with saline.
An audit of hospital records showed multiple discrepancies in Clampitt’s handling of controlled substances during the time he worked for the hospital, which had been less than a month. Investigators later learned that in 2019, a separate hospital had employed Clampitt and discovered discrepancies in its records that suggested he might have been diverting drugs for his own use. That hospital fired Clampitt after he refused to submit to a drug test.
As part of his guilty plea, Clampitt admitted that he knew that his activities resulted in one or more critically ill patients receiving diluted fentanyl, which lacked prescribed quantities of active medication necessary to control pain. Having been deprived of medically necessary medication, such patients would endure pain and suffering and were exposed to increased risks of illness and death, stemming from, among other things, possible infection and respiratory, cardiovascular, and musculoskeletal complications.
This case was investigated by the U.S. Food and Drug Administration, Office of Criminal Investigations, and the Jacksonville Sheriff’s Office – Pharmaceutical Diversion & Designer Drug Unit attached to the North Florida High Intensity Drug Trafficking Area. It was prosecuted by Assistant United States Attorney Michael J. Coolican.
USAO - Florida, Middle